Alyeska Investment Group
CRDF icon

Alyeska Investment Group’s Cardiff Oncology CRDF Stock Holding History

Alyeska Investment Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-75,000
Closed -$1.06M – 525
2020
Q3 		$1.06M Buy
+75,000
New +$495K 0.02% 387

Other funds holding CRDF

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group's CRDF Position: Q4 2020 in Review

Alyeska Investment Group sold out of Cardiff Oncology (CRDF) in Q4 2020, closing a stake of 75,000 shares — an estimated $1.06M sold.

Alyeska Investment Group first reported a position in CRDF in Q3 2020 and held it in 1 quarter. The position peaked at $1.06M in Q3 2020. 82 funds tracked by Wall St. Rank hold CRDF as of Q4 2020.

  • Alyeska Investment Group reported no remaining Cardiff Oncology position as of Q4 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 75,000 Cardiff Oncology shares in Q4 2020, an estimated $1.06M.
  • Alyeska Investment Group first reported a position in Cardiff Oncology in Q3 2020 and held it in 1 quarter.
  • Alyeska Investment Group's Cardiff Oncology position peaked at $1.06M in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2020.

Based on Alyeska Investment Group's 13F filing for Q4 2020, filed 16 Feb 2021.